Accredited Industry-Supported Symposium Lunch: Peripheral Arterial Diseases and Plasmid DNA Therapy: From Current Standards of Care to Emerging Clinical Innovation
90 min
Friday, October 16, 2026
12:15 PM - 1:45 PM
Supported by an educational grant from PERI and AnGes, Inc..
This session will award 1.00 pharmacotherapeutic contact hour.
Learning Objectives:
1. Review the current standard of care and treatment approaches for patients with arterial ulcers associated with peripheral arterial disease (PAD).
2. Examine the scientific rationale and clinical development of plasmid DNA therapy, including key findings from two decades of clinical investigation.
3. Analyze the design, methodology, and clinical outcomes of the LEGEND-1 registrational trial evaluating investigational gene therapy in patients with moderate peripheral arterial disease and ulcers.
4. Evaluate wound validation methodologies and review clinical case data from the pivotal trial to better understand patient selection, wound assessment, and treatment outcomes.
This session will award 1.00 pharmacotherapeutic contact hour.
Learning Objectives:
1. Review the current standard of care and treatment approaches for patients with arterial ulcers associated with peripheral arterial disease (PAD).
2. Examine the scientific rationale and clinical development of plasmid DNA therapy, including key findings from two decades of clinical investigation.
3. Analyze the design, methodology, and clinical outcomes of the LEGEND-1 registrational trial evaluating investigational gene therapy in patients with moderate peripheral arterial disease and ulcers.
4. Evaluate wound validation methodologies and review clinical case data from the pivotal trial to better understand patient selection, wound assessment, and treatment outcomes.
-
ISS Speaker
-
Charles Zelen DPM -
David Armstrong DPM, MD, PhD -
Dennis Orgill MD, PhD -
John Lantis MD -
-